Truist Securities Maintains Hold Rating for Amgen, Raises Price Target to $319.00 USD

Truist Securities maintains its "Hold" rating on Amgen (AMGN) with a price target increase from $318.00 to $319.00 USD, a 0.31% increase. The rating and target price adjustments signify Truist Securities' consistent outlook on AMGN, keeping its status unchanged while showing a slight upward adjustment in expected value. Amgen is a leader in biotechnology-based human therapeutics and continues to attract varied analysis from top financial experts.